Last reviewed · How we verify
BLT
BLT is a composite tissue allograft transplant procedure that replaces damaged or missing limbs and associated tissues with donor tissue.
BLT is a composite tissue allograft transplant procedure that replaces damaged or missing limbs and associated tissues with donor tissue. Used for Severe limb loss or amputation with potential for functional restoration, Patients unsuitable for or unsatisfied with prosthetic alternatives.
At a glance
| Generic name | BLT |
|---|---|
| Also known as | BLT (Benzocaine 20%, lidocaine 6%, tetracaine 4%) |
| Sponsor | Dartmouth-Hitchcock Medical Center |
| Modality | Small molecule |
| Therapeutic area | Transplantation / Reconstructive Surgery |
| Phase | FDA-approved |
Mechanism of action
BLT (Biologic Limb Transplantation) involves surgical transplantation of a whole limb or limb segment from a deceased donor to restore form and function in patients with severe limb loss. The procedure requires lifelong immunosuppression to prevent rejection of the allograft tissue. It is distinct from prosthetic limbs in that it provides living tissue with potential for nerve regeneration and functional recovery.
Approved indications
- Severe limb loss or amputation with potential for functional restoration
- Patients unsuitable for or unsatisfied with prosthetic alternatives
Common side effects
- Acute rejection
- Chronic rejection / graft-versus-host disease
- Immunosuppression-related infections
- Immunosuppression-related malignancy
- Surgical complications
Key clinical trials
- Bright Light Therapy for Non-motor Symptoms in Parkinson's Disease (NA)
- Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine (NA)
- Promoting Cognitive Resilience and Reducing Frailty in Older Veterans With Bright Light Therapy (NA)
- Bright Light Therapy for OSA (NA)
- Comparison of Compounded Topical Anesthetics (PHASE4)
- Bright Light Therapy for Depressed Geriatric Inpatients (PHASE2)
- Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease (NA)
- Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |